Investor directory

Sambrinvest

Sambrinvest S.A. is a private equity and venture capital firm specializing in direct and fund of funds investments. Within direct investments, it focuses on startup, spin-out, spin-off, growth capital and turnaround investments. It does not invest in the retail, hospitality or banking and insurance industries. It invests in the following sectors: Agri-Food, audiovisual, gaming, automotive, biotechnology, pharmaceuticals, wholesale, construction, digital, environmental, alternative energy, manufacturing, computing, electronics, services, services to people, tourism, transportation, logistics and real estate. The firm is also open for investments in other sectors. The firm seeks to invest in small and medium sized companies in the Charleroi Sud-Hainaut and Thuin districts of Belgium. It invests in the form of a minority stake, subordinated loan or participating capital loan, subscription to a bond issue, unsecured loan or repayable advance, and participation in the acquisition of industrial property rights. It typically invests at most €1.25 million ($1.70 million) in companies with a turnover below €50 million ($68 million). Sambrinvest S.A. was founded on January 9, 1985 and is based in Gosselies, Belgium.

Focus

Seed RoundSeries BScale StageCharitySeries AShow more
http://www.sambrinvest.be
https://crunchbase.com/organization/sambr-invest
https://linkedin.com/company/17940318
https://twitter.com/sambrinvest
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=98023

Louis-François Binon

CFO

Fabrice Carosella

Investment Manager

Xavier Daive

Deputy Director and Head of Unit

Louis Henne

Investment Manager

Sébastien Lemploy

Investment Manager

Olivier Mertens

Head of Digital Unit

Maxime Moulin

Investment Manager

Flavia Pati

Investment Manager

Helena Pozios

Head of Life Sciences Unit

Anne Prignon

CEO

Maxime Van Der Schrick

Investment Manager

Micheline Streel

Investment Manager

Philippe Tielemans

Investment Manager

45 past transactions

ExeVir Bio

Series A in 2020
ExeVir Bio BV develops single-domain antibody-based therapies that help patients ward off viral infections. It develops VHH72-FC, that binds to a highly conserved region on the spikes of SARS-CoV-2, which are essential for the virus to enter the cell. The company was founded in 2020 and is based in Zwijnaarde, Belgium.

Sortlist

Series B in 2021
Because finding the right partner in the fast-growing digital environment is a hard task, we have built an online multi-criteria searching tool strongly linked to professional networks and peer-to-peer recommendations. Sortlist helps marketing managers find their partners in minutes and let them focus on building communication and marketing success. Start your search now on www.sortlist.com

Cake App

Seed Round in 2022
Cake App mission is to become the leading software technology provider that analyzes financial data to help people better understand, control and improve their finances, supported by a business model that shares our revenue with users.

PDC*line Pharma

Series B in 2021
PDC*line Pharma is a French-Belgium clinical-stage biotech company that develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line) loaded with cancer antigens. PDC*line Pharma originated from a flagship R&D program of the French Blood Bank (EFS, Etablissement Français du Sang) where PDC*line, a proprietary Plasmacytoid Dendritic Cell line (PDC) was developed from a patient with a PDC leukemia. Laurent LEVY President France & COO, and Joel PLUMAS, CSO founded the company in April 2014 in Grenoble and took the project to the clinical development stage with non-dilutive funding. Eric Halioua joined the team in February 2016, and became President and CEO in July 2016.

Opinum

Series A in 2016
Opinum has created and ensures the continuous development of the "Opinum Data Hub" platform, designed for energy and environmental actors. Opinum is the key partner of these actors in their digital transformation journey. Opinum Data Hub covers all stages of the data management value chain to allow its users to look beyond the complexity of data and focus on their core value and expertise. Opinum Data Hub is mainly intended for large private and public service companies, energy suppliers and companies with expertise in energy management (ESCO).

PDC line Pharma SAS

Private Placement in 2020
PDC line Pharma SAS, a clinical-stage biotech company, researches and develops a class of antigen–specific active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells with cancer antigens. Its products under pipeline include PDC*mel, a drug candidate for melanoma; and PDC*lung, a drug candidate for lung cancer. The company was founded in 2014 and is based in La Tronche, France with additional offices in Lyon, France and Angleur, Belgium. It also has a research laboratory in La Tronche, France.

Hirering

Seed Round in 2021
HireRing is the on-demand staffing platform connecting employers with top professional recruiters per vacancy request, and for the hiring fee they set upfront. Their platform makes it fast and easy for employers to submit their hiring needs to the adequate recruitment agencies, and for agencies to choose the adequate business opportunities to work on.

Aerospacelab

Series B in 2022
Aerospacelab SA develops and manufactures satellites equipped with sensors. The company also develops tools to automate tasks using artificial intelligence and machine learning. Aerospacelab SA was founded in 2017 and is headquartered in Mont-Saint-Guibert, Belgium.

Minoryx

Series B in 2018
Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.

Smartbeam

Seed Round in 2019
Smartbeam is a construction-tech startup solving construction problems with technology solutions. We are developing a budget management application for construction that helps every site stakeholders (general contractors, subcontractors, architects and developers) to work together from the tendering phase to the end of the project. Our team is made of Construction, Business and Software Engineers and we are currently working with experienced construction partners to co-develop the software and create a modern vision of construction budget management 2.0.

Utopix Pictures

Private Placement in 2019
Utopix is a team determined to find the perfect photographer/videographer for you and will help carry out all your business projects. At Utopix, they know that a picture is worth a thousand words. But they also know that it is difficult to find the right professional who is able to transform your ideas into images quickly and easily.

Apaxen

Private Placement in 2019
Apaxen operates as a biotechnology company, which develops anti-inflammatory and antifibrotic molecules to treat pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). It provides macrophage migration inhibitory factor (MIF), MFC-1040, and molecule MIF inhibitor for the treatment of pulmonary arterial hypertension. It offers services, which includes pipeline, MIF as a therapeutic target in PAH, research and development strategy, and MFC-1040 solutions. The company was founded in 2018 and is based in Gosselies, Belgium.

Cognivia

Private Placement in 2019
Tools4patient.SA. develops tools for clinical development of new medicines. The company’s product includes Placebell, which is a solution that improves test sensitivity by characterizing and managing the individual placebo response in a variety of disease states where the placebo effect masks the true efficacy of potentially important therapies. Tools4patient.SA. was founded in 2013 and is headquartered in Charleroi, Belgium.

Commuty

Seed Round in 2019
With Commuty, they save money while reducing constraints and increasing flexibility. Smart parking management organises company managed parking spots allocationsand bookings according to their parking policy. Bicycle raising connects cyclers with similar routes, organises the use of shared bicycles and automates kilometer refund. Ride sharing elevation connects riders, automates ride sharing tax advantage and organises guaranteed return.

Minoryx

Private Placement in 2018
Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.

Sortlist

Series A in 2019
Because finding the right partner in the fast-growing digital environment is a hard task, we have built an online multi-criteria searching tool strongly linked to professional networks and peer-to-peer recommendations. Sortlist helps marketing managers find their partners in minutes and let them focus on building communication and marketing success. Start your search now on www.sortlist.com

X4C

Seed Round in 2016
Monolayer chemical coating technology

Ncardia

Venture Round in 2017
Pluriomics is a Leiden (The Netherlands) based biotech company focused on development of fully functional human assay systems for use in drug discovery and development. Based on their novel proprietary methods for differentiation of stem cells they develop highly functional cell types like their Pluricyte Cardiomyocytes. They use these cells in combination with phenotypic assays to deliver high quality results.

AbolerIS Pharma

Series A in 2023
AbolerIS Pharma operates as a biotech company that engages in the development of immune-modulators for the treatment of transplant rejection, graft-versus-host-disease, and auto-immune diseases. The company’s products include Anti-CD45RC, a monoclonal antibody that deplete effector T cells; and IL-34, cytokine to induce tolerogenic macrophages and regulatory T cells. AbolerIS Pharma was incorporated in 2019 and is based in Nantes, France.

cikisi

Seed Round in 2023
Specialized in Web Intelligence (collecting, searching and filtering web information). Help companies and organizations to take advantage of Web information that are relevant to their development. Develops and commercializes Cikisi WMT, a Web Intelligence Solution.

Opinum

Seed Round in 2015
Opinum has created and ensures the continuous development of the "Opinum Data Hub" platform, designed for energy and environmental actors. Opinum is the key partner of these actors in their digital transformation journey. Opinum Data Hub covers all stages of the data management value chain to allow its users to look beyond the complexity of data and focus on their core value and expertise. Opinum Data Hub is mainly intended for large private and public service companies, energy suppliers and companies with expertise in energy management (ESCO).

Subleeme SA

Private Placement in 2018
Subleeme SA, traded as Bsit, develops mobile application to provide babysitter services. The company was founded in 2015 and is based in Brussels, Belgium.

Shyfter

Seed Round in 2021
We bring simplicity in the management of staff schedules. Shyfter is a web and app-based platform to facilitate day to day management problems related to staff scheduling. Our role is firstly to make it easier to connect employers and employees through a single and intuitive platform and secondly to eliminate a whole series of administrative and legal problems related to staff scheduling.

HeartKinetics

Convertible Note in 2021
HeartKinetics is a developer of a smart wireless connected device to provide a measure of cardiac contractility together with the traditional electrocardiogram.

Subleeme SA

Private Placement in 2019
Subleeme SA, traded as Bsit, develops mobile application to provide babysitter services. The company was founded in 2015 and is based in Brussels, Belgium.

Amyl Therapeutics

Series A in 2021
Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β (Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.

Calyos

Venture Round in 2012
Calyos SA specializes in the development, manufacturing, and commercialization of two-phase thermal management and cooling systems. The company offers its products for high power semiconductors, such as IGBT power modules and electronic components; and electrical engines cooling and energy storage applications. Calyos SA was founded in 2011 and is based in Jumet, Belgium.

Cognivia

Series B in 2019
Tools4patient.SA. develops tools for clinical development of new medicines. The company’s product includes Placebell, which is a solution that improves test sensitivity by characterizing and managing the individual placebo response in a variety of disease states where the placebo effect masks the true efficacy of potentially important therapies. Tools4patient.SA. was founded in 2013 and is headquartered in Charleroi, Belgium.

Piximate

Private Placement in 2020
Piximate empowers businesses by delivering tailor-made computer vision AI boosting productivity while saving costs. Any valued information from images and videos is built through our platform and is easily accessible through our API. We simply connect cameras or e-commerce website into Piximate, train the model through automated and manual annotations. We have already ready to use products for the retail industry and can deploy very rapidly our technology to other industries such as automotive, healthcare, security, fashion or construction.

OncoDNA

Private Placement in 2019
OncoDNA, with over 60 years’ expertise in medical diagnostics, was founded by a team of experts with many years of experience in DNA sequencing and diagnostic analyses in oncology.

Opinum

Series A in 2016
Opinum has created and ensures the continuous development of the "Opinum Data Hub" platform, designed for energy and environmental actors. Opinum is the key partner of these actors in their digital transformation journey. Opinum Data Hub covers all stages of the data management value chain to allow its users to look beyond the complexity of data and focus on their core value and expertise. Opinum Data Hub is mainly intended for large private and public service companies, energy suppliers and companies with expertise in energy management (ESCO).

Team Corner SPRL

Private Placement in 2019
Team Corner SPRL provides digital agencies matching services for businesses to find their marketing and communication agencies. It offers Sortlist, a Web application that enables businesses to find digital agencies in their industry; compare agencies on relevant data; and access qualitative reviews written by fellow marketers. It lists agencies in beverage, food, automotive, and other sectors. The company also enables businesses to search in various categories, such as digital strategy, branding and positioning, ergonomy (UX/UI), content strategy, e-commerce, Web application, Website creation, design, motion design, movie clip, mobile app, copywriting, social media, gaming, event, SEO, media planning, advertising, e-mailing, online advertising, 3D, public relations, and photography. The company was founded in 2014 and is based in Brussels, Belgium.

Ncardia

Series B in 2017
Pluriomics is a Leiden (The Netherlands) based biotech company focused on development of fully functional human assay systems for use in drug discovery and development. Based on their novel proprietary methods for differentiation of stem cells they develop highly functional cell types like their Pluricyte Cardiomyocytes. They use these cells in combination with phenotypic assays to deliver high quality results.

InhaTarget Therapeutics

Private Placement in 2020
InhaTarget Therapeutics develops dry powder inhalation (DPI) formulations to improve the treatment of chronic respiratory diseases. It provides cisplatin-based and paclitaxel-based dry powder inhalation. The company was founded in 2018 and is based in Brussels, Belgium.

Utopix Pictures

Seed Round in 2019
Utopix is a team determined to find the perfect photographer/videographer for you and will help carry out all your business projects. At Utopix, they know that a picture is worth a thousand words. But they also know that it is difficult to find the right professional who is able to transform your ideas into images quickly and easily.

Commuty

Private Placement in 2019
With Commuty, they save money while reducing constraints and increasing flexibility. Smart parking management organises company managed parking spots allocationsand bookings according to their parking policy. Bicycle raising connects cyclers with similar routes, organises the use of shared bicycles and automates kilometer refund. Ride sharing elevation connects riders, automates ride sharing tax advantage and organises guaranteed return.

ChromaCure

Venture Round in 2018
ChromaCure will launch a drug development program to identify potential new candidates that selectively and potently inhibit cancer targets and potentially provide novel therapy for multiple forms of cancer, either as monotherapy or in combination with immunotherapy or chemotherapy.

OncoDNA

Series B in 2020
OncoDNA, with over 60 years’ expertise in medical diagnostics, was founded by a team of experts with many years of experience in DNA sequencing and diagnostic analyses in oncology.

Sunrise

Series A in 2023
Sunrise aims to bring simple answers to millions of people suffering from sleep disorders. We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate as in-lab sleep studies, at a fraction of the cost. Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases. Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.